Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,516.27 98.74 0.68%
TOPIX 1,173.37 6.78 0.58%
HANG SENG 22,760.24 64.23 0.28%

Synergy Pharmaceuticals to Begin Trading on The NASDAQ Global Market



Synergy Pharmaceuticals to Begin Trading on The NASDAQ Global Market

NEW YORK, Feb. 11, 2013 (GLOBE NEWSWIRE) -- Synergy Pharmaceuticals Inc.
(Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal disorders
and diseases, today announced that its common stock has been approved for
listing on The NASDAQ Global Market under the symbol "SGYP." Trading on The
NASDAQ Global Market is expected to commence on February 12, 2013. The
Company's units and warrants will continue to trade on The NASDAQ Capital
Market under the symbols "SGYPU" and "SGYPW," respectively.

About Synergy Pharmaceuticals Inc.

Synergy is a biopharmaceutical company focused on the development of new drugs
to treat gastrointestinal disorders and diseases. Synergy's lead proprietary
drug candidate, plecanatide, is a synthetic analog of the human
gastrointestinal hormone uroguanylin, and functions by activating the
guanylate cyclase C receptor on epithelial cells of the GI tract. Synergy
completed a positive Phase I study of plecanatide in healthy volunteers, and
positive Phase IIa and Phase IIb/III clinical trials in patients with chronic
idiopathic constipation (CIC). Detailed positive findings from a recently
completed Phase IIb/III clinical trial will be presented at a major scientific
meeting this year. Synergy is also developing plecanatide for the treatment of
irritable bowel syndrome with constipation (IBS-C), having initiated the first
trial in IBS-C patients in late 2012. Synergy's second GC-C agonist, SP-333,
is in clinical development to treat inflammatory bowel diseases, and has just
completed its first Phase I trial in healthy volunteers. More information is
available at http://www.synergypharma.com.

CONTACT: Media Contact:
         Janet Skidmore
         Office: 215-658-4915
         Mobile: 215-429-2917
         skidmorecomm@earthlink.net
        
         Investor Contact:
         Danielle Spangler
         The Trout Group
         synergy@troutgroup.com
         (646) 378-2924
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement